Research and Development
To achieve this, we are focused on deep science, innovation, and collaboration as we work to create new treatments for heart failure and other cardiovascular diseases, and to bring transformative medicines to patients in areas of high unmet need.
Cardurion KK Drug Discovery Unit
Cardurion KK, is the preclinical Drug Discovery unit of Cardurion, our Japanese subsidiary. Cardurion KK is based in Shonan, Japan and has a team of 14 highly experienced cardiovascular drug discovery scientists led by Shota Ikeda, Ph.D.
Capabilities
The team at Cardurion KK specializes in leveraging cutting-edge medicinal chemistry, computational molecular modeling and design, molecular biology, including genetic engineering. Cardurion KK has state-of-the-art laboratories for organic chemistry, biology facilities, and robust knowledge and expertise in cardiovascular research.
Accomplishments
Working together, the Cardurion KK team has advanced our first CaMKII inhibitor molecule into clinical development. The Cardurion KK team is currently progressing additional CaMKII inhibitors through preclinical development and identifying new drug candidates for other cardiovascular targets.
Our Pipeline
See how Cardurion’s pipeline is expanding, positioning us for rapid growth across multiple indications. Please note that the safety and efficacy of the agents below are under investigation and have not been established.
PROGRAM
DISCOVERY
PRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3/PIVOTAL
PDE9 Inhibitors
CRD-740
Heart Failure (HFpEF & HFrEF)
Stage: Phase 2 / 2B
CRD-750
Heart Failure (HFrEF)
Stage: Phase 2 / 2B
CaMKII Inhibitors
CRD-4730
CVPT, Other CV Disease
Stage: Phase 2 / 2B
IV program
CV Disease
Stage: Pre-Clinical
2nd Oral program
CV Disease
Stage: Discovery
TRPC6 Inhibitor
Preclinical program
Fibrotic CMPs
Stage: Discovery
CMP: Cardiomyopathies
CPVT: Catecholaminergic polymorphic ventricular tachycardia
CV: Cardiovascular
